6-K - Clearmind Medicine Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Clearmind Medicine Inc. announced successful ongoing treatment of participants in the third cohort of its FDA-approved Phase I/IIa clinical trial evaluating CMND-100 for Alcohol Use Disorder at Yale University and Johns Hopkins University, with no serious adverse events reported to date. This progress follows the March 11, 2026 enrollment advancement and reflects confidence in CMND-100's safety and tolerability.

Key Takeaways

1Third cohort treatment ongoing at Yale University and Johns Hopkins University.

2No serious adverse events reported.

3Follows March 11, 2026 announcement of third cohort enrollment advancement at Yale, Johns Hopkins, and Tel Aviv Sourasky Medical Center.

4Phase I/IIa multinational multicenter trial for CMND-100 in moderate to severe AUD.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE TITLED: "CLEARMIND MEDICINE REPORTS SUCCESSFUL ONGOING TREATMENT OF PARTICIPANTS AT US SITES IN ITS FDA-APPROVED CMND-100 PHASE I/IIA CLINICAL TRIAL FOR ALCOHOL USE DISORDER"